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Abstract
Background: Little is known on the magnitude and correlates of insulin resistance in HIV-infected people in Africa. We
determined the prevalence of insulin resistance and investigated associated factors in HIV-infected adult Cameroonians.
Methods: We conducted a cross-sectional study at the Yaoundé Central Hospital, Cameroon; during
which we enrolled HIV-infected people aged 30 to 74 years with no previous history of cardiovascular disease. An
homeostatic model assessment of insulin resistance (HOMA-IR) like index served to assess insulin sensitivity with insulin
resistance defined by values of 2.1 or higher.
Results: We included 452 patients (20% men). Their mean age was 44.4 ± 9.8 years and 88.5% of them were on
antiretroviral therapy (93.3% on first line regimen including Zidovudine, lamivudine and Efavirenz/Nevirapine). Of all
participants, 28.5% were overweight, 19.5% had obesity and 2.0% had diabetes. The prevalence of insulin resistance
was 47.3% without any difference between patients on ART and those ART-naïve (48.5% vs. 38.5%; p = 0.480). Obesity
was the only factor independently associated with insulin resistance (adjusted odds ratio: 2.28; 95% confidence
interval: 1.10–4.72).
Conclusion: Insulin resistance is present in nearly half of HIV-infected patients in Cameroon despite a low prevalence
rate of diabetes, and is associated with obesity.
Keywords: Insulin resistance, HOMA-IR, HIV, Cameroon
Background
Insulin resistance is a metabolic disorder characterized
by a decrease in sensitivity of insulin receptors within
target cells, resulting in the failure of insulin to achieve
the desired effect [1]. The condition may occur during
puberty and pregnancy, in the context of diseases such
as obesity, type 2 diabetes, dyslipidemia and ovarian dys-
function, or secondary to continuous use of medications
such as steroids [2]. Insulin resistance is associated with
high cardiovascular morbidity and mortality [3]. Further-
more, there is growing evidence that insulin resistance
can appear in the course of HIV infection, especially
after antiretroviral therapy (ART) initiation [4].
Several studies have reported high prevalence of insu-
lin resistance and other metabolic abnormalities in
people living with HIV, including hypertriglyceridemia
and low levels of high density lipoproteins (HDL-C).
These metabolic abnormalities seem to be more pre-
ponderant among patients on ART, especially those on
protease inhibitors-containing regimen [5, 6]. The preva-
lence of insulin resistance in HIV-infected individuals
varies between 13 and 47.7% [7].
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In Africa the epicenter of HIV infection, little is known
on the magnitude and correlates of insulin resistance
among HIV-infected people. The present study was
conducted to determine the prevalence of insulin
resistance and associated factors among an HIV-infected
African population.
Methods
Study design, setting and participants
This was a cross-sectional study with participants re-
cruited between December 2015 and May 2016 at the
HIV day-care unit of the Yaoundé Central Hospital,
Cameroon. This health care facility is one of the most
important HIV clinics in Cameroon, providing special-
ized care to almost 12,000 HIV-infected persons. The
staff of this center includes general practitioners and
specialized physicians who are frequently trained in the
management of HIV infection. All Blood samples were
analyzed at the biochemistry laboratory of the Yaoundé
University Teaching Hospital and at the Laboratory of
Molecular Medicine and Metabolism, University of
Yaoundé 1 Biotechnology Center, Cameroon. The study
was approved by the Cameroon National Ethics Committee
for Human Health Research (Ethical approval N° 2015/12/
710/CE/CNERSH/SP). All consenting clinically stable HIV-
infected patients aged 30 to 74 years, with no history of
cardiovascular disease and routinely followed at the study
site were eligible, unless they were receiving lipid-lowering
therapy or hormone therapy, were pregnant or breastfeed-
ing women.
Data collection
We used a standardized and pre-tested questionnaire to
collect data on general characteristics such as age and
gender, history of HIV infection including duration since
diagnosis, ART regimen and duration, CD4 count of less
than 6 months and viral load of less than 1 year, and his-
tory of hypertension and/or diabetes.
Weight was measured to the nearest 0.1 kg using an
electronic scale (CAMRY, Hong Kong, China); with the
participant standing up on the scale without shoes and
heavy clothing, looking straight ahead, arms stretching
along the body. Height was measured to the nearest
0.1 cm using a stadiometer; with the participant standing
up without shoes and hat, looking straight ahead, arms
stretching along the body. Body Mass Index (BMI) was
then derived as weight (kg)/height*height (m2), and partic-
ipants grouped into 4 categories: underweight (< 18.5),
normal (18.5–24.9), overweight (25.0–29.9) or obese
(≥30.0) [8]. Waist and hip circumferences were measured
to the nearest 0.1 cm using a measuring tape; the waist-
to-hip ratio (WHR) was then calculated. Abdominal obes-
ity was defined in accordance with the IDF criteria (waist
circumference > 90 cm for men and >80 cm for women)
[9]. We used an electronic sphygmomanometer (Omron
M5–1, Omron Healthcare, Kyoto, Japan) for blood pres-
sure measurement. Hypertension was defined as a systolic
blood pressure (SBP) ≥ 140 mmHg and/or a diastolic
blood pressure (DBP) ≥ 90 and/or self-reported history of
ongoing antihypertensive medication use [10].
Blood sampling and laboratory investigations
Blood samples were aseptically collected after a 12-h over-
night fasting, by venipuncture of the brachial vein in a
5 ml sodium fluoride tube and a 5 ml dry tube without a
tourniquet or fist clenching. Thereafter, they were kept on
ice (4 °C) and immediately transported to the biochemis-
try laboratory where plasma and serum specimen were
separated accordingly, by centrifugation at 3.000 rpm for
5 min. Fasting plasma glucose (FPG) and lipids including
total cholesterol (TC), triglycerides (TG) and HDL-C
were assayed without delay using standard colorimetric
methods. Using the Friedwald’s formula, low density lipo-
proteins cholesterol (LDL-C) was calculated when TG
levels were below 4 mmol/L, and measured when TG
values were over 4 mmol/L [11]. Serum was aliquoted and
stored at −20 °C for further measurement of C-Peptide.
C-Peptide was measured within 6 weeks using a previ-
ously validated sandwich immunoassay method [12].
Dyslipidemia was considered in the presence of ele-
vated levels of TC (> 6.2 mmol/L) and/or an elevated
level of LDL-C (> 4.1 mmol/L) and/or a low HDL-C
level (< 1.04 mmol/L in men and 1.29 mmol/L in
women) and/or an elevated level of TG (≥ 1.7 mmol/L)
[13]. We considered as having diabetes any patient with
at least 2 FPG levels ≥7.0 mmol/L on two occasions at
least 48 h apart, or self-reported history of antidiabetic
medications after the diagnosis was made in a health
facility [14]. Metabolic syndrome was defined using the
International Diabetes Federation (IDF) criteria [9].
Determination of Insulin sensitivity
We used an HOMA-IR like index for insulin sensitivity
assessment; it was determined by the HOMA-IR formula:
FPG (mmol/L) x insulin (mU/L or μUl/mL) / 22.5) [15];
where the insulin level was replaced by the C-peptide
level. The C-peptide measurement was use to access insu-
lin level base on their equimolar secretion in blood. In
fact, the measurement of insulin would have not be easy
according to our facilities; however, we decided to meas-
ure the C-peptide because it is co-secreted in equimolar
concentration with insulin, it is not metabolized by the
liver and does not undergo any extraction during the first
hepatic passage [16]. Therefore, it can be indirectly
measured to access insulin secretion [16]. Insulin resist-
ance was defined by any value of the HOMA-IR like index
equal or above 2.1; this threshold was defined in an HIV-
infected population in Peru [7].
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Statistical analysis
Data were analyzed using SPSS v. 23 (IBM Corporation,
Chicago, Illinois, USA). Results are presented as count
(percentage) for categorical variables, and mean ± stand-
ard deviation (SD) or median (25th–75th percentiles) for
quantitative variables. The Student t-test, chi-square test
or equivalents served for groups’ comparison. Logistic
regressions were then used to investigate the determi-
nants of insulin resistance. The basic models included
age, sex and each candidate predictor of interest. Ex-
panded multivariable models included age and sex, and
significant variables in basic models, based on a thresh-
old p-value <0.25 from which backward elimination was
used to retain the final independent predictors of insulin
resistance. A p-value <0.05 was used to characterize sta-
tistically significant results.
Results
Characteristics of the study population
Four hundred and 52 patients (452) were included,
among whom 91 (20.1%) were males. The mean age was
44.4 ± 9.8 years. The duration since diagnosis of HIV in-
fection ranged from 2 days to 204 months with a median
of 84 months (25th–75th percentiles: 36–108). Of the
452 included patients, 400 (88.5%) were on ART. Dur-
ation of ART varied between 1 and 179 months, with a
median of 72 months (25th–75th percentiles: 35–108).
Only 6.7% of participants were on second-line treatment,
protease inhibitors containing regimen especially; no
third line treatment was reported.
BMI, waist circumference and WHR were higher in
patients on ART than in ART-naïve ones (Table 1).
Obesity and abdominal obesity were significantly
more prevalent in ART treated in comparison to their
ART-naïve counterparts (Table 1). The mean values
of blood pressure were 124 ± 23 mmHg for SBP and
81 ± 14 mmHg for DBP (Table 1).
Of the 452 participants, 331 (73.9%) had a recent CD4
count of less than 6 months in their files. The values
ranged between 2 and 1800 cells/mm3 with a median of
375 cells/mm3 (25th–75th percentiles: 245–527) (Table 1).
C-peptide values ranged from 2.4 to 342.6 mU/L, with
a median of 9.1 mU/L (25th–75th percentiles: 6.8–13.5)
and no difference between ART+ and ART- patients.
The mean value of FPG was 5.1 ± 0.9 mmol/L; 9 partici-
pants (2.0%) had diabetes (Table 1). The prevalence of
dyslipidemia was 33.8%. Overall, 11.7% of participants
had metabolic syndrome, with no difference between
ART+ and ART- patients (Table 1).
Insulin resistance and associated factors in the study
population
The median HOMA-IR like index was 2.0 (25th–75th
percentiles: 1.4–3.2). In all, 214 (47.3%) participants were
insulin resistant, with 88.7% of them on ART and 9.9%
having diabetes. Diabetes (IR+ vs. IR-: 3.3% vs. 0.8%,
p = 0.027), obesity (29.0% vs. 10.9%, p = 0.006), abdominal
obesity (52.3% vs. 34.9%, p = 0.025) and to some extent
hypertension (17.8% vs. 9.2%, p = 0.064) were more fre-
quent in participants with insulin resistance than in those
without. In age and sex adjusted analyses, obesity (odds
ratio [OR]: 2.50; 95% CI: 1.24–5.06), abdominal obesity
(OR: 2.45; 95% CI: 1.03–4.89) and diabetes (OR: 8.96; 95%
CI: 1.06–71.21) were significantly associated with insulin
resistance (Table 2). In expanded multivariable logistic re-
gression models, general obesity remained the only factor
independently associated with insulin resistance (OR: 2.28;
95% CI: 1.10–4.72; p = 0.027) (Table 3).
Discussion
In this study including HIV-infected Cameroonians, we
found a high prevalence of insulin resistance, affecting
nearly half of participants with no previous cardiovascu-
lar disease. In these relatively young patients with insulin
resistance, diabetes was frequent, as affecting one in ten
participants. Moreover, obesity appeared as an independ-
ent factor which explains insulin resistance occurrence
in these patients. Preventing and controlling obesity in
our HIV-infected population, will likely lead to a reduc-
tion or delay in insulin resistance occurrence, as well as
related harmful consequences.
The prevalence of insulin resistance in our sample was
higher than previously reported by several studies like
that of Guillen and co-workers in a large HIV-infected
population in Peru; based also on the HOMA-IR like
index and applying the same threshold definition [7].
This difference can be explained by the fact that basal
insulin secretion seems higher in subjects of African ori-
gins compared to others [17]. However, our prevalence
is within the range previously described in the literature,
that is between 13 and 47.7% [7, 18]. Discrepancies ob-
served between studies may be partly due to the method
used to assess insulin sensitivity. In fact, although the
general trend is towards using the HOMA-IR index,
there is no current consensus on which method should
be used for insulin sensitivity evaluation among HIV-
infected patients. Moreover, even when using indirect
assessment tools like the HOMA-IR index, the main
difficulty remains the threshold to consider in defining
insulin resistance, since this threshold may vary depend-
ing on race, gender and even some pathologies [19].
Diabetes was present in one participant out of ten with
insulin resistance. This high prevalence of diabetes in
this relatively young population can be explained by the
role of insulin resistance as a predicting factor for
diabetes [20]. General obesity and abdominal obesity
were also frequent in our study population; these high
prevalences are in contrast with weight loss frequently
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reported in HIV-infected populations [21]. These results
show how important it is to avoid compensatory over-
nutrition in this high risk population.
General obesity remained the only factor associated to
insulin resistance after adjusting for other factors in
multivariable analysis. These results are similar to those
reported by Geffner and co-workers who described gen-
eral obesity as the factors more closely associated with
insulin resistance diagnosed by HOMA-IR index in a co-
hort of US HIV-infected children and adolescents [22].
Similarly, Guillen and co-workers showed an association
between greater body mass index and insulin resistance
diagnosed by HOMA-IR index in HIV-infected adults in
Peru [7]. On the other hand and in line with Guillen and
co-workers’ findings, we did not observe an association
between insulin resistance and ART; even when the ART
regimen comprised protease inhibitors. These results
differ from those previously reported [6, 23]. Moreover,
there is convincing evidence that development of insulin
resistance and other abnormalities of glucose metabolism
in the context of HIV infection can have multiple origins
including continuous ART, and inflammatory reactions
associated with chronic HIV infection [18, 24].
Our study has some limitations. First, its cross-
sectional design does not allow us to conclude on a
causative-relationship between insulin resistance and
Table 1 Characteristics of the study population
Overall (n = 452) ART – (n = 52) ART + (n = 400) p
Clinical characteristics
Mean age (years) 44.4 ± 9.8 43.7 ± 9.9 44.7 ± 9.9 0.064
Mean systolic Blood pressure (mmHg) 123.4 ± 22.5 124.0 ± 23.6 123.3 ± 22.4 0.849
Mean diastolic blood pressure (mmHg) 81.3 ± 13.5 82.0 ± 14.7 81.2 ± 13.4 0.700
Hypertension, n (%) 60 (13.3) 11 (21.1) 49 (12.3) 0.075
Mean body mass index (kg/m2) 25.8 ± 5.3 24.0 ± 4.8 26.0 ± 5.3 0.006
Obesity, n (%) 218 (48.0) 14 (26.9) 203 (50.8) 0.001
Mean waist circumference (cm) 82.1 ± 11.6 78.1 ± 10.9 82.6 ± 11.6 0.007
Abdominal obesity, n (%) 195 (43.1) 12 (25.0) 182 (45.5) 0.005
Mean hip circumference (cm) 95.1 ± 11.2 90.7 ± 9.5 95.6 ± 11.7 0.001
Mean waist/hip ratio 0.86 ± 0.07 0.86 ± 0.07 0.86 ± 0.07 0.744
Biological characteristics
Median CD4 count (cells/mm3) 375 (245–532) 352 (173–600) 375 (258–523) 0.933
Undetectable Viral load (≤ 60 copies/ml), n (%) 72/84 (85.7) 2/2 (100) 70/82 (85.5) >0.999
Mean fasting glycaemia (mmol/L) 5.1 ± 0.9 4.9 ± 1.1 5.1 ± 0.9 0.134
Diabetes, n (%) 9 (2.0) 1 (1.9) 8 (2.0) 0.970
Mean total cholesterol (mmol/L) 4.5 ± 1.0 4.0 ± 1.0 4.5 ± 1.0 0.001
Hypercholesterolaemia, n (%) 26 (5.8) 1 (1.9) 25 (6.3) 0.341
Mean HDL-cholesterol (mmol/L) 1.7 ± 0.6 1.2 ± 0.5 1.7 ± 0.6 < 0.001
Low HDL, n (%) 106 (23.5) 28 (55.3) 78 (19.5) < 0.001
Mean triglycerides (mmol/L) 1.0 ± 0.5 1.1 ± 0.5 1.0 ± 0.5 0.233
Hypertriglyceridaemia, n (%) 35 (7.7) 4 (7.7) 31 (7.8) 0.988
Mean LDLcholesterol (mmol/L) 2.3 ± 0.9 2.3 ± 0.8 2.3 ± 0.9 0.739
High LDL cholesterol, n (%) 17 (3.8) 1 (1.9) 16 (4.0) 0.707
Any dyslipidemia, n (%) 153 (33.8) 30 (57.7) 123 (30.8) < 0.001
Median C-peptide 9.1 (6.8–13.5) 9.2 (8.0–15.4) 9.1 (6.6–12.6) 0.860
Median HOMA-IR like index 2.0 (1.4–3.2) 1.9 (1.4–2.8) 2.0 (1.4–3.0) 0.219
Insulin resistance, n (%) 214 (47.3) 20 (38.5) 194 (48.5) 0.480
Metabolic syndrome, n (%) 53 (11.7) 3 (5.8) 50 (12.5) 0.156
Values are count (percentages), mean ± standard deviation or median (25th–75th percentiles)
HDL high density lipoproteins, LDL low density lipoproteins, ART + Participants on antiretroviral therapy, ART- participants naïve to antiretroviral therapy
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identified associated factors. Second, our sampling
method was not random and we recruited our patients
from only one site, this can be a source of bias and may
hamper the generalization of our findings to the entire
Cameroonian HIV-infected population. Third, we used
C-peptide measurement to access insulin level base on
their equimolar secretion in blood. In fact, the measure-
ment of insulin would have not be easy according to our
facilities; however, we decided to measure the C-peptide
because it is co-secreted in equimolar concentration
with insulin, it is not metabolized by the liver and does
not undergo any extraction during the first hepatic
passage [16]. Therefore, it can be indirectly measured
to access insulin secretion [16]. Finally, we used an
HOMA-IR like index to access insulin sensitivity instead
of the hyperinsulinemic euglycemic clamp. Which is the
reference method, though very demanding and time-
consuming [25]. Nonetheless, several indices including the
HOMA-IR have been developed to facilitate this
assessment. It is true that Sobngwi and co-workers dem-
onstrated that fasting insulin sensitivity indices like
HOMA-IR are modest predictors of insulin sensitivity
measured by euglycemic clamp in non-diabetes African
subjects [26], Noteworthy, Bonora and co-workers bol-
stered a strong correlation between the HOMA-IR and
the hyperinsulinemic euglycemic clamp in the general
population, which enabled them to recommend using the
HOMA-IR in conditions where realization of the clamp
Table 2 Factors associated with insulin resistance
Variables Modalities IR + (n = 214) IR - (n = 238) Crude odds ratio (95% CI) p aAge and sex adjusted
odds ratio (95% CI)
p
Gender - Male 36 (16.8) 55 (23.1) 0.67 (0.37–1.44) 0.355
- Female 178 (83.2) 183 (76.9) 1
Age - ≥ 46 84 (39.3) 90 (37.8) 1,06 (0.54–3.68) 0.480
- < 46 130 (60.7) 148 (62.2) 1
HIV duration ≥ 12 months 194 (90.7) 224 (94.1) 0.61 (0.32–1.23) 0.613 0.73 (0.29–1.82) 0.500
< 12 months 20 (9.3) 14 (5.9) 1 1
ART - yes 194 (90.7) 206 (86.6) 1.51 (0.54–3.68) 0.480 1.27 (047–3.41) 0.634
- no 20 (9.3) 32 (13.4) 1 1
1st line with NNRTIs - yes 211 (98.6) 162 (68.1) 1.40 (0.76–1.02) 0.372 0.92 (0.30–1.70) 0.457
- no 13 (1.4) 14 (31.9) 1 1
2nd line with PIs - yes 10 (4.7) 17 (7.1) 0.64 (0.15–2.84) 0.722 0.66 (0.15–2.87) 0.576
- no 179 (95.3) 194 (92.9) 1 1
Metabolic syndrome - yes 35 (16.4) 18 (7.6) 2.39 (0.84–4.28) 0.120 1.79 (0.76–4.19) 0.178
- no 179 (83.6) 220 (92.4) 1 1
Hypertension - yes 38 (17.8) 22 (9.2) 2.12 (0.96–3.92) 0.064 1.89 (0.92–3.85) 0.079
- no 176 (82.2) 216 (90.8) 1 1
Diabetes - yes 7 (3.3) 2 (0.8) 4.00 (1.02–71.20) 0.027 8.96 (1.06–76.21) 0.044
- no 207 (96.7) 236 (99.2) 1 1
Obesity - yes 62 (29.0) 26 (10.9) 3.32 (1.30–4.84) 0.006 2.50 (1.24–5.06) 0.011
- no 152 (71.0) 212 (89.1) 1 1
Abdominal obesity - yes 112 (52.3) 83 (34.9) 2.05 (1.17–4.40) 0.025 2.45 (1.03–4.89) 0.041
- no 102 (47.7) 155 (65.1) 1 1
Dyslipidemia - yes 65 (30.4) 88 (37.0) 0.74 (0.37–1.35) 0.286 0.72 (0.37–1.40) 0.337
- no 149 (69.6) 150 (63.0) 1 1
CD4 count - ≥ 350 89 (41.6) 101 (42.4) 1.30 (0.60–2.85) 0.508 1.31 (0.59–2.89) 0.508
- < 350 57 (58.4) 84 (57.6) 1 1
Detectable viral load - yes 8 (3.7) 4 (1.7) 2.50 (0.20–31.80) 0.583 / /
- no 32 (96.3) 40 (98.3) 1 1
aAdjusted for: age and gender. Factors are presented as count (percentage)
ART antiretroviral therapy, NNRTIs non-nucleoside reverse transcriptase inhibitors, IR + participants with insulin resistance, IR- participants without insulin resistance
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method is not easy [27]. Moreover, to the best of our
knowledge, there is no a study which determined the
HOMA-IR threshold or the estimated percentile to de-
fine insulin resistance in African population; therefore,
we used a threshold which was non-specific to our
study population. Notwithstanding these limitations,
our sample size was relatively high and we used rigor-
ous methodological and statistical procedures to exam-
ine our research questions.
Conclusion
Insulin resistance may be highly prevalent in the black
African HIV-infected population, perhaps mainly driven
by obesity. This calls for the implementation or
strengthening of obesity prevention programs in the
HIV-infected population in other to prevent or post-
pone the occurrence of insulin resistance and related
complications.
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NNRTIs non-nucleoside reverse transcriptase inhibitors, PIs protease inhibitors, IR + participants with insulin resistance, IR- participants without insulin resistance
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